Table 2 Baseline characteristics between CTX and CNIs group
CTX | CNIs | P value | |
|---|---|---|---|
Patients | 45 | 46 | |
Gender (M:F) | 28:17 | 29:17 | 0.935 |
Age (year) | 55.18 ± 13.48 | 52.39 ± 16.34 | 0.377 |
PLA2R-associated % | 82.2% (37/45) | 89.1% (41/46) | 0.346 |
Previously used ACEI/ARB % | 37.8% (17/45) | 30.4% (14/46) | 0.460 |
Urine Protein (g/24 h) | 5.87 (4.28, 9.53) | 4.93 (3.66, 7.33) | 0.096 |
Albumin (g/L) | 19.48 ± 6.13 | 20.03 ± 5.45 | 0.650 |
Creatinine (μmmol/L) | 94.95 ± 37.48 | 74.37 ± 23.93 | 0.003* |
Cholesterol (mmol/L) | 7.80 ± 2.30 | 7.64 ± 2.90 | 0.769 |
Triglyceride (mmol/L) | 2.02 (1.78, 3.53) | 2.09 (1.68, 3.04) | 0.504 |
Systolic Pressure (mmHg) | 132.05 ± 19.03 | 128.62 ± 16.24 | 0.364 |
Diastolic pressure (mmHg) | 80.73 ± 9.33 | 80.82 ± 10.82 | 0.965 |
Side effects | 7 | 5 | 0.509 |
Pneumonia | 1 | 3 | 0.625 |
Hepatic dysfunction | 2 | 1 | 0.985 |
Myelosuppression | 1 | 0 | 0.495 |
Neoplasm of bladder | 1 | 0 | 0.495 |
Intracranial hemorrhage | 1 | 0 | 0.495 |
Gastrointestinal hemorrhage | 1 | 0 | 0.495 |
Renal function deterioration | 0 | 1 | 0.495 |